| abstract |
The invention relates to a pharmaceutical preparation of a non-glycosylized t-PA derivative, K2P pro, with an enzymatic activity of at least 1.4 MU/ml and a pH of 4.5 to 6.5, containing citrate and at least one compound from the following group: a) ascorbic acid, b) EDTA, c) amino compounds of formula R?1R?2N - R - X, where X = SO3?H, CH(NH2?)-CO2?H, CO2?H, H, NH2? or OH, R = C1?-C9? alkylene, preferably C4?-C7? alkylene, C3?-C6? cycloalkylene or benzylidene and R?1 and R?2, independently of each other, are H or C1?-C3? alkyl, d) guianidine analogs of formula (II), where Y = H2?N+ or 0, Z = H or (CH2?)m? V, (CH2?)m?CH(NH2?)-CO2?H, CH(CO2?H)-(CH2?)m?CO2?H, V = NH2? or CO2?H and m = 1 to 4, e) carboxylic acids substituted with one or more hydroxyl, keto and/or further carboxyl groups, f) dimethylbiguanide, g) pyrimidine nucleosides and pyrimidine nucleotides, h) trehalose, glucosamine. The invention also relates to a drug based on the t-PA derivative K2P pro as the active ingredient and a process for producing it. |